TY  - GEN
N2  - This  Note  explores  the  abuses  to  IPR  and  the  stock  market  by  hedge  funds,  and  abuses  by  pharmaceutical  companies  to  the  patent  system as a whole, and poses a solution that will prevent these abuses. In Part I, this Note will discuss patent basics, the PTAB’s role, and the IPR process. It will also examine, in detail, the patent trolling technique hedge  funds  are  using.  Additionally,  it  will  address  what  actions  the  PTAB  has  taken,  and  is  likely  to  take,  if  any,  to  prevent  the  hedge  funds’  conduct.  Lastly,  Part  I  will  explore  the  monopolistic  hold  the  pharmaceutical  industry  has  on  drug  pricing.  Part  II  of  this  Note  will  examine  the  legislative  responses  to  hedge  funds’  abuse  of  IPR  by  analyzing  proposed  patent  reform  bills  in  Congress,  and  whether  those  bills  will  affect  the  problem  at  hand.  This  Part  will  also  address  the  pharmaceutical  industry’s  push  for  an  exception  to  IPR.  In  Part  III  of  this  Note,  a  policy  solution  will  be  proposed  that  advocates  for  higher  standards for pharmaceutical companies to obtain drug patents, and for regulatory  changes  that  allow  for  quicker  entry  to  the  market  by  generics.  Moreover,  Part  III  will  discuss  how  these  policies  can  be  implemented and why they will work.
AB  - This  Note  explores  the  abuses  to  IPR  and  the  stock  market  by  hedge  funds,  and  abuses  by  pharmaceutical  companies  to  the  patent  system as a whole, and poses a solution that will prevent these abuses. In Part I, this Note will discuss patent basics, the PTAB’s role, and the IPR process. It will also examine, in detail, the patent trolling technique hedge  funds  are  using.  Additionally,  it  will  address  what  actions  the  PTAB  has  taken,  and  is  likely  to  take,  if  any,  to  prevent  the  hedge  funds’  conduct.  Lastly,  Part  I  will  explore  the  monopolistic  hold  the  pharmaceutical  industry  has  on  drug  pricing.  Part  II  of  this  Note  will  examine  the  legislative  responses  to  hedge  funds’  abuse  of  IPR  by  analyzing  proposed  patent  reform  bills  in  Congress,  and  whether  those  bills  will  affect  the  problem  at  hand.  This  Part  will  also  address  the  pharmaceutical  industry’s  push  for  an  exception  to  IPR.  In  Part  III  of  this  Note,  a  policy  solution  will  be  proposed  that  advocates  for  higher  standards for pharmaceutical companies to obtain drug patents, and for regulatory  changes  that  allow  for  quicker  entry  to  the  market  by  generics.  Moreover,  Part  III  will  discuss  how  these  policies  can  be  implemented and why they will work.
T1  - Patent System Manipulation :Hedge Funds Abusing IPR, Poor Patent Quality & Pharmaceutical Monopolies
AU  - Costa, Kenneth J.
LA  - eng
ID  - 41979
KW  - Patents
KW  - Pharmaceuticals
KW  - Hedge fund
SN  - 0736-7694
TI  - Patent System Manipulation :Hedge Funds Abusing IPR, Poor Patent Quality & Pharmaceutical Monopolies
LK  - http://www.cardozoaelj.com/wp-content/uploads/2017/02/35.1-Costa.pdf
UR  - http://www.cardozoaelj.com/wp-content/uploads/2017/02/35.1-Costa.pdf
ER  -